← Back
Data updated: Sep 20, 2026
KENVUE BRANDS
Specialty Pharmaceuticals
KENVUE BRANDS is a specialty pharmaceutical company with 29 FDA-approved products.
1984
Since
29
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
20 Small Molecules
KENVUE BRANDS's Key Drugs
KENVUE BRANDS's core commercial portfolio centers on TYLENOL WITH NAPROXEN — its most strategically important drugs approved in the last 15 years.
KENVUE BRANDS's Recent FDA Approvals
KENVUE BRANDS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
KENVUE BRANDS's Therapeutic Areas
Disease areas where KENVUE BRANDS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
KENVUE BRANDS Pipeline Snapshot
Active clinical trials for KENVUE BRANDS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TYLENOL WITH NAPROXEN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1984-05-18
- Latest
- 2026-07-24
- Applications
- 27